Trial Profile
A Placebo-Controlled, Double-Blind, Randomized, Cross Over Pilot Study Of The Efficacy And Tolerability Of Incobotulinum Toxin A (Xeomin) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Dystonia
- Focus Therapeutic Use
- 22 Sep 2021 Primary endpoint has been met. (efficacy- dystonia severity and musical performance at week 8 following the final cycle injection), as per Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
- 22 Sep 2021 Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
- 29 Jul 2020 Status changed from recruiting to completed.